2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Thomas G. Martin, MD, discusses the patient population of the phase 2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.
Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California San Francisco (UCSF), co-leader, Cancer Immunology & Immunotherapy Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the patient population of the phase 2 CARTITUDE-1 study (NCT03548207) in relapsed/refractory multiple myeloma.
The CARTITUDE-1 study examined ciltacabtagene autoleucel (cilta-cel), a novel CAR T-cell therapy, in relapsed/refractory multiple myeloma, Martin says. Cilta-cel features 2 single-domain binding antibodies that bind to BCMA, and the intracellular signaling domain is 4-1BB and CD3ζ, Martin explains.
Updated results from the phase 2 study were presented at the 2021 ASH Annual Meeting & Exposition, Martin continues. Phase 2 of the study evaluated patients who received a median of 6 prior lines of therapy, and 88% of patients were triple-class refractory, underscoring the heavily pretreated nature of this population, Martin concludes.